Metraipolis › archive › dc_8b82cd801475

Patient-derived organoids (PDOs): a novel preclinical platform to overcome challenges in cancer immunotherapy — Europe PMC PMID:41788310

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41788310
DOI
10.3389/fcell.2026.1757516
License (as archived)
solo-consultazione
Archived
2026-11-05T16:32:36.187Z
SHA-256 of the archived text
73f12a433e0cd0b8c731227c8454924e509622c2978365d1a112d3e2065bce44
Stable URL of this page
https://metraipolis.com/documento/dc_8b82cd801475

How to cite

Patient-derived organoids (PDOs): a novel preclinical platform to overcome challenges in cancer immunotherapy — Europe PMC PMID:41788310 — Europe PMC (en), https://europepmc.org/article/MED/41788310 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8b82cd801475 (Metraipolis archive dc_8b82cd801475, sha256 73f12a433e0cd0b8c731227c8454924e509622c2978365d1a112d3e2065bce44)
BibTeX
@misc{dc8b82cd801475,
  title = {Patient-derived organoids (PDOs): a novel preclinical platform to overcome challenges in cancer immunotherapy — Europe PMC PMID:41788310},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41788310},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8b82cd801475; sha256 73f12a433e0cd0b8c731227c8454924e509622c2978365d1a112d3e2065bce44},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41788310. Agents can read the archived copy with the MCP tool read_document.